Gene therapy commonly uses viral vectors to integrate corrective genetic sequences into cellular genomes. Generally accepted as the least immunogenic and least toxic option, adeno-associated viruses (AAVs) have emerged as the most popular vector candidate in recent years. To use AAVs for clinical gene therapy applications, they must be produced in sufficient quantities to meet clinical demand. However, setting up and optimizing AAV production is a meticulous process.
Download this ebook from Thermo Fisher Scientific to learn about
- The role of AAVs in gene therapy
- How to manufacture AAVs
- Moving from discovery to clinical and commercial manufacturing